Study demonstrates superiority, showing both statistically significant and clinically meaningful reduction in annualized bleeding rate with a generally well-tolerated safety profile compared to ...

Pfizer Inc. PFE on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab) ...

An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM.

Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...

Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth by more than eight months, according to a study that may expand its use.

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...

Pfizer said its blood-cancer treatment met the main goal of an ongoing late-stage study, significantly extending the time patients lived without their disease worsening compared with a standard drug ...

This real-world study, conducted between September and December 2024, also showed that the impact of symptoms on daily activities, including work and family responsibilities, was lower in recipients ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to ...